Adaptimmune reported a net loss of $47.6 million for Q1 2025, consistent with the prior year, on total revenue of $7.3 million, up from $5.7 million in Q1 2024. The increase was primarily due to $4.0 million in Tecelra product sales following its FDA approval. The company also provided 2025 Tecelra full-year sales guidance of $35-$45 million and reported total liquidity of $60 million as of March 31, 2025.

Adaptimmune reported a Q4 2024 product revenue of $1.2 million from Tecelra, with 3 patients apheresed in 2024 and 10 in Q1 2025, indicating accelerating launch momentum. The company completed a corporate restructure and is implementing additional cost reductions, aiming for profitability by 2027, and ended 2024 with $152 million in total liquidity.

Adaptimmune reported Q3 2024 financial results, highlighted by revenue of $40.9 million and total liquidity of $186.1 million. The company is restructuring to focus on its sarcoma franchise and high-potential R&D programs, targeting operating breakeven in 2027.

Adaptimmune reported Q2 2024 financial results, highlighted by FDA approval for Tecelra and revenue increase due to the Genentech collaboration termination. The company had a net profit of $69.5 million and total liquidity of $214.8 million.

Adaptimmune reported a revenue of $5.7 million for the first quarter ended March 31, 2024, compared to $47.6 million for the same period in 2023. The company's cash and cash equivalents were $140.7 million as of March 31, 2024. Adaptimmune believes its cash runway will extend into late 2025, supported by anticipated revenues from afami-cel and other income sources.

Adaptimmune reported Q4 2023 revenue of $0.2 million and a net loss of $47.9 million. The company's cash and cash equivalents totaled $143.9 million as of December 31, 2023. Adaptimmune is preparing to launch afami-cel in Q3 2024.

Adaptimmune reported revenue of $7.3 million and a net loss of $45.6 million for the third quarter ended September 30, 2023. The company's cash runway is confirmed into early 2026.

Adaptimmune reported revenue of $5.1 million and a net loss of $21.4 million for the second quarter ended June 30, 2023. The company completed a strategic combination with TCR2, adding pipeline, technologies, approximately 40 people and $84.6 million in Total Liquidity at closing. They also anticipate completing the afami-cel BLA submission in Q4 2023 and have a cash runway into early 2026.

Adaptimmune reported revenue of $47.6 million and a net profit of $1.0 million for the first quarter ended March 31, 2023. The company completed submission of the clinical module of the afami-cel BLA and announced a strategic combination with TCR2.

Adaptimmune Therapeutics reported Q4 2022 revenue of $11.0 million compared to $1.4 million for the same period in 2021. The net loss for the fourth quarter was $29.3 million ($(0.03) per ordinary share), compared to $38.9 million ($(0.04) per ordinary share) for the same period in 2021.

Adaptimmune reported revenue of $7.0 million and a net loss of $41.4 million for the third quarter ending September 30, 2022. The company is focusing on advancing its SURPASS family of trials and its wholly owned late-stage preclinical optimized PRAME TCR.

Adaptimmune reported financial results for the second quarter ended June 30, 2022. Revenue was $5.5 million, Total Operating Expenses were $49.3 million, and Net Loss was $44.5 million.

Adaptimmune reported financial results for the first quarter ended March 31, 2022. The company's revenue increased primarily due to an increase in development activities under collaboration arrangements. They had cash and cash equivalents of $89.5 million and Total Liquidity of $304.2 million as of March 31, 2022.

Adaptimmune reported fourth quarter revenue of $1.4 million and is focused on filing its first BLA, building its MAGE-A4 franchise, scaling up its manufacturing capabilities, and making progress with its allogeneic platform in 2022. The company's cash, cash equivalents and marketable securities are expected to fund operations into early 2024.

Adaptimmune made significant strides in Q3 with encouraging SURPASS trial data, the initiation of a Phase 2 trial with ADP-A2M4CD8, and the announcement of a strategic collaboration with Genentech. The company's cash, cash equivalents, and marketable securities, along with upfront payments from Genentech, are expected to fund operations into early 2024.

Adaptimmune reported financial results for the second quarter ended June 30, 2021. The company had cash and cash equivalents of $50.5 million and Total Liquidity of $285.4 million. Revenue for the quarter was $3.1 million, and the company believes its existing funds will support operations into early 2023.

Adaptimmune reported first quarter financial results, with a revenue of $0.4 million and a net loss of $37.8 million. The company's cash and cash equivalents totaled $32.4 million, and total liquidity reached $317.9 million. Financial guidance confirmed funding into early 2023.

Adaptimmune reported a revenue of $1.5 million and a net loss of $36.6 million for the fourth quarter of 2020. The company's total liquidity was $368.2 million as of December 31, 2020, and it believes that its existing cash, cash equivalents and marketable securities will fund operations into early 2023.

Adaptimmune reported their Q3 financial results and business update, highlighting upcoming data presentations at SITC and CTOS, and confirming financial guidance into 2022. Recruitment into clinical trials has been steadily recovering following the first wave of COVID-19.